Antibiotic De-escalation in Sepsis

At 48–72 hours after empiric antibiotics are started, make an explicit prescribing decision rather than allowing the initial regimen to continue by default. Review (1) whether infection remains the best explanation for organ dysfunction, (2) whether a source has been identified and controlled, (3) microbiology and susceptibility data, including preliminary Gram stain and rapid molecular results when available, and (4) the patient’s hemodynamic and clinical trajectory. PubMed+2PubMedConsiderations for Empiric Antimicrobial Therapy in Sepsis and ...PubMedLaboratory Evaluation of Sepsis - StatPearls - NCBI BookshelfPubMedBackground and definition of the decision problem - Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi – a systematic review and economic evaluation - NCBI Bookshelf

Assign one of four actions: stop all antibiotics when the diagnostic evaluation supports a noninfectious syndrome or infection is unlikely; narrow to the least-broad active regimen when a pathogen and susceptibility profile are available; discontinue redundant agents from empiric combination therapy; or continue/revise therapy when infection remains probable but microbiology, source control, or clinical response is unresolved. A confirmed microbiological diagnosis with susceptibilities is an indication to de-escalate unnecessary or excessively broad therapy. Wolters Kluwer+2Wolters KluwerExecutive Summary: Surviving Sepsis Campaign:... - LippincottPubMedConsiderations for Empiric Antimicrobial Therapy in Sepsis and ...PubMedEarly Recognition and Initial Management of Sepsis in Adult Patients

Build the review into sepsis operations rather than relying on ad hoc recall. Electronic 72-hour antibiotic time-outs and checklist-based prompts have increased de-escalation and reduced antibiotic duration in ICU-oriented stewardship interventions. Hospital sepsis programs should integrate antibiotic-stewardship expertise and local microbiology data into the review process. PubMed+1PubMedConsiderations for Empiric Antimicrobial Therapy in Sepsis and ...CDCHospital Sepsis Program Core Elements - CDC

Treat preliminary microbiology as an early stewardship trigger. Gram stain from a positive blood culture should be communicated promptly because it can alter therapy before final susceptibility testing; where available, rapid molecular testing from positive cultures can identify organisms and resistance-associated genetic markers within hours. These results should prompt removal of agents no longer needed, while final susceptibility data confirm the definitive regimen. PubMedPubMedLaboratory Evaluation of Sepsis - StatPearls - NCBI Bookshelf

Negative cultures do not automatically justify discontinuation in sepsis or septic shock. A substantial proportion of severe sepsis and septic shock episodes are culture-negative despite bacterial or fungal infection, and negative microbiology must be interpreted alongside prior antimicrobial exposure, adequacy of sampling, syndrome-specific diagnostic studies, and the clinical trajectory. PubMed+1PubMedSurviving Sepsis Campaign: International Guidelines for ... - PMCWHO[PDF] Strengthening Clinical Diagnostic Stewardship in the Western ... - IRIS

Failure to improve should trigger a diagnostic and source-control reassessment before simply prolonging broad-spectrum treatment. Reevaluate the presumed anatomic source, whether drainage or another procedure is required, whether the sampled site represents the active infection, and whether the syndrome may be noninfectious. If no infectious diagnosis remains credible after this reassessment, discontinue antimicrobials rather than extending empiric treatment. PubMed+1PubMedConsiderations for Empiric Antimicrobial Therapy in Sepsis and ...PubMedEarly Recognition and Initial Management of Sepsis in Adult Patients

Do not use procalcitonin to decide whether to initiate antimicrobials in suspected sepsis. Initial antimicrobial treatment should be driven by the clinical assessment of infection severity and the consequences of withholding therapy; procalcitonin is better positioned as an adjunct during serial reassessment of treatment duration. PubMed+1PubMedConsiderations for Empiric Antimicrobial Therapy in Sepsis and ...PubMedLaboratory Evaluation of Sepsis - StatPearls - NCBI Bookshelf

For a hemodynamically stable patient receiving antibiotics for suspected bacterial sepsis, serial procalcitonin supports earlier discontinuation when the value is below 0.5 µg/L or has decreased by more than 80% from its peak. One randomized trial used daily procalcitonin measurement with nonbinding advice to stop after 72 hours when procalcitonin was below 0.5 ng/mL, or when it had fallen by 80% from peak if the baseline was above 2 ng/mL. ScienceDirect+1ScienceDirectUse of procalcitonin point-of-care testing to guide de-escalation of antibiotic therapy in adults with suspected bacterial sepsis in a tertiary hospital in Bangladesh: a randomised controlled open-label trial - ScienceDirectPubMedLaboratory Evaluation of Sepsis - StatPearls - NCBI Bookshelf

Use the biomarker only after checking that the patient is clinically improving, the infectious diagnosis has been reconsidered, and no source-control issue or syndrome-specific reason for prolonged treatment remains. In the ADAPT-Sepsis randomized trial of 2,760 critically ill adults with suspected sepsis, a daily procalcitonin protocol reduced total antibiotic duration with noninferior all-cause mortality compared with standard care. JAMAJAMABiomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis

Do not assume benefit generalizes to every host population. In critically ill patients with cancer and sepsis, serial procalcitonin-guided management did not reduce antibiotic duration in the Pro-Can randomized trial. When procalcitonin conflicts with an unstable clinical course, unresolved infection, or a microbiologically documented indication for ongoing therapy, prioritize the clinical and microbiologic assessment. Wolters Kluwer+1Wolters KluwerProcalcitonin-Guided Management and Duration of Antibiotic... : Critical Care ExplorationsPubMedConsiderations for Empiric Antimicrobial Therapy in Sepsis and ...

Empiric combination therapy should usually be reduced promptly once susceptibility data are available. Earlier Surviving Sepsis Campaign guidance advised limiting empiric combination therapy to 3–5 days and de-escalating to the most appropriate single agent once susceptibilities are known. Exceptions include selected endocarditis requiring prolonged combination therapy and circumstances in which aminoglycoside monotherapy would be considered, which should generally be avoided, particularly for Pseudomonas aeruginosa sepsis. PubMedPubMedSurviving Sepsis Campaign: International Guidelines for ... - PMC

Use heightened caution in neutropenic patients with severe sepsis and in infections involving difficult-to-treat multidrug-resistant organisms, including Acinetobacter and Pseudomonas species. In these settings, the adequacy of initial therapy, definitive susceptibility profile, infection site, and clinical response should be reviewed before reducing spectrum or dropping combination coverage. PubMedPubMedSurviving Sepsis Campaign: International Guidelines for ... - PMC

If microbiologic diagnosis and susceptibility testing are available, current Surviving Sepsis Campaign guidance recommends de-escalation over no de-escalation. The certainty of evidence is very low, so decisions should remain source-specific and patient-specific rather than protocol-driven when the patient has persistent shock, inadequate source control, or an infection requiring a specialized regimen. Wolters KluwerWolters KluwerExecutive Summary: Surviving Sepsis Campaign:... - Lippincott

For every antibiotic continued after the 48–72-hour review, document the presumed or confirmed infection, relevant microbiology, source-control status, current regimen rationale, and the next reassessment trigger. A complete review should produce a defined stop, narrowing, substitution, or continuation decision rather than a nonspecific plan to “continue antibiotics.” PubMed+1PubMedConsiderations for Empiric Antimicrobial Therapy in Sepsis and ...PubMedBackground and definition of the decision problem - Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi – a systematic review and economic evaluation - NCBI Bookshelf

Monitor for opportunities to remove excess spectrum as microbiology matures. Final susceptibility testing, rather than the initial empiric regimen’s apparent clinical success, should anchor directed therapy when a pathogen is recovered. De-escalation includes both discontinuation of unnecessary drugs and spectrum narrowing; it is not limited to switching between antibiotics. Wolters Kluwer+1Wolters KluwerExecutive Summary: Surviving Sepsis Campaign:... - LippincottWolters KluwerAntibiotic de-escalation in the ICU : Current Opinion in Infectious Diseases

At the hospital level, align sepsis and stewardship programs rather than treating them as competing priorities. The CDC identifies stewardship engagement, local microbiology-informed recommendations, and mechanisms to review antibiotics initiated for suspected sepsis for tailoring, discontinuation, or completion as core operational elements. CDCCDCHospital Sepsis Program Core Elements - CDC